Nature Communications (May 2023)
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer
- Isabel Tundidor,
- Marta Seijo-Vila,
- Sandra Blasco-Benito,
- María Rubert-Hernández,
- Sandra Adámez,
- Clara Andradas,
- Sara Manzano,
- Isabel Álvarez-López,
- Cristina Sarasqueta,
- María Villa-Morales,
- Carmen González-Lois,
- Esther Ramírez-Medina,
- Belén Almoguera,
- Antonio J. Sánchez-López,
- Laura Bindila,
- Sigrid Hamann,
- Norbert Arnold,
- Christoph Röcken,
- Ignacio Heras-Murillo,
- David Sancho,
- Gema Moreno-Bueno,
- María M. Caffarel,
- Manuel Guzmán,
- Cristina Sánchez,
- Eduardo Pérez-Gómez
Affiliations
- Isabel Tundidor
- Department of Biochemistry and Molecular Biology, Complutense University
- Marta Seijo-Vila
- Department of Biochemistry and Molecular Biology, Complutense University
- Sandra Blasco-Benito
- Department of Biochemistry and Molecular Biology, Complutense University
- María Rubert-Hernández
- Department of Biochemistry and Molecular Biology, Complutense University
- Sandra Adámez
- Department of Biochemistry and Molecular Biology, Complutense University
- Clara Andradas
- Brain Tumor Research Program, Telethon Kids Institute
- Sara Manzano
- Breast Cancer Group, Oncology Area, Biodonostia Health Research Institute
- Isabel Álvarez-López
- Breast Cancer Group, Oncology Area, Biodonostia Health Research Institute
- Cristina Sarasqueta
- Unit of Information and Healthcare Results, OSI Donostialdea, Biodonostia Health Research Institute
- María Villa-Morales
- Centro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM)
- Carmen González-Lois
- Department of Pathology, Hospital Universitario Puerta de Hierro, Majadahonda
- Esther Ramírez-Medina
- Department of Obstetrics & Gynecology, Hospital Universitario Puerta de Hierro, Majadahonda
- Belén Almoguera
- Department of Obstetrics & Gynecology, Hospital Universitario Puerta de Hierro, Majadahonda
- Antonio J. Sánchez-López
- Biobank Hospital Universitario Puerta de Hierro Majadahonda
- Laura Bindila
- Clinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical Center
- Sigrid Hamann
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein
- Norbert Arnold
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein
- Christoph Röcken
- Institute of Pathology, University Hospital Schleswig-Holstein
- Ignacio Heras-Murillo
- Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- David Sancho
- Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- Gema Moreno-Bueno
- MD Anderson International Foundation; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM); Department of Biochemistry, Autonomous University of Madrid; Instituto de Investigación Hospital Universitario La Paz (IdiPaz); Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
- María M. Caffarel
- Breast Cancer Group, Oncology Area, Biodonostia Health Research Institute
- Manuel Guzmán
- Department of Biochemistry and Molecular Biology, Complutense University
- Cristina Sánchez
- Department of Biochemistry and Molecular Biology, Complutense University
- Eduardo Pérez-Gómez
- Department of Biochemistry and Molecular Biology, Complutense University
- DOI
- https://doi.org/10.1038/s41467-023-38750-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 15
Abstract
Abstract Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.
